Diastolic Dysfunction and TAVR: Prognosis before and after Procedure

The PARTNER 2 SAPIEN 3 showed baseline diastolic dysfunction is a predictor of clinical events after 2 years of TAVR. As expected, improved diastolic function after procedure immediately changes prognosis. 

Función diastólica y TAVI

Though these outcomes did meet our expectations, very few studies have shown hard evidence linking diastolic dysfunction and aortic stenosis. 

All patients included in the PARTNER 2 SAPIEN 3 registry received an echocardiogram at baseline, at 30 days, one, and two years, to look into diastolic dysfunction, and were classified according to the American Society of Echocardiography diastolic dysfunction groups. 

Of 1750 patients in the registry, 682 (54.4%) showed diastolic dysfunction grade 1, 352 (28.1%) had grade 2 and 168 (13.4%) had grade 3. The rest of patients (4.1%) were undetermined.  

Diastolic dysfunction grade was associated to increased death and hospitalization at 1 and 2 years (p<0.002) and all cause death at 2 years (p=0.01).


Read also: Last Bastion of Bare Metal Stents Finally Falls.


70.8% of patients showed improved diastolic function after valve implantation. Those who showed at least one grade improvement in calcification after procedure showed reduced mortality and hospitalization rates at one year (p<0.001) and increased survival rate at 2 years (p=0.01).

A simple transthoracic echocardiogram 30 days after procedure can provide information on hard points at mid and long -term. 

Conclusion

The PARTNER 2 SAPIEN 3 has shown that baseline diastolic dysfunction, and its improvement after TAVR, can predict hard events at 2 years, including death. 

j-jacc-2020-10-032free

Original Title: Diastolic Function and Clinical Outcomes After Transcatheter Aortic Valve Replacement PARTNER 2 SAPIEN 3 Registry.

Reference: Geraldine Ong et al. J Am Coll Cardiol 2020;76:2940–51. https://doi.org/10.1016/j.jacc.2020.10.032


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....